Joshua A. Kazam, Director at Nile Therapeutics, Inc. (NLTX), bought 510 shares at $0.75 ($383) on 2009-03-12, disclosed to the SEC on 2009-03-13.
Open-market purchase of $382 NLTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| EAGL | BUY | 2019-03-01 | $101K | — | Filing → |
| CAPR | BUY | 2015-01-22 | $25K | — | Filing → |
| NLTX | BUY | 2008-12-16 | $4K | — | Filing → |